Caris Life Sciences (Caris), a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionise healthcare, has announced that the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Caris Precision Oncology Alliance (POA).
The POA is a growing network of leading cancer centres across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimise standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
The University of Maryland Greenebaum Comprehensive Cancer Center is one of the top cancer treatment and research centres in the country. In 2016, the National Cancer Institute (NCI) elevated UMGCCC to its highest designation as a comprehensive cancer centre, a designation that was renewed in 2021, making it one of only 53 NCI-designated comprehensive cancers in the nation.
Located in Baltimore, Maryland, UMGCCC offers innovative approaches to diagnosing and treating all types of cancer, conducts cutting-edge research to bring the latest advances in cancer treatment directly to patients in Maryland and beyond and provides cancer screening and patient education services. The cancer centre is nationally recognised for its excellence in patient care and multidisciplinary translational research.